Study S001560

A Randomized, Double-blinded, Single-centre, Parallel-group, Placebo-controlled, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Neuropathy.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02138045
Acronym: TODINELI
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 39
Start: 2014-05
Primary completion: 2017-02
Lead sponsor: Aalborg University Hospital
Conditions: Diabetes Mellitus, Type 1; Type 1 Diabetes Mellitus
Interventions: DRUG:Placebo treatment; DRUG:Liraglutide treatment
Results posted: FALSE

Registered primary outcomes

RIII withdrawal reflex activity (using standard electromyography) [After 6 months of treatment with Liraglutide]
Evoked brain potentials (using standard electroencephalographic brain imaging). [After 6 months of treatment with Liraglutide]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022903	Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy. Arendt Nielsen T, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics	2022	Randomized trial	PMID 34918951 DOI	cites ClinicalTrials.gov:NCT02138045; registry reference DERIVED:34918951
R0012788	Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy. Brock C, British journal of clinical pharmacology	2019	Randomized trial	PMID 31338868 DOI	cites ClinicalTrials.gov:NCT02138045; registry reference DERIVED:31338868